SEC Filing Summary for Arbutus Biopharma Corp

Robert A. Beardsley, a director at Arbutus Biopharma Corp, was granted 78,800 stock options on June 8, 2026. These options are exercisable immediately and expire on June 8, 2036. The exercise price is $4.24 per share, reflecting the closing price of the company's common shares on the Nasdaq Stock Market on the grant date. This transaction is reported on Form 4, indicating a change in beneficial ownership. Mr. Beardsley acquired these options directly.